Posts

Showing posts with the label endoxaban

atrial fibrillation: treating subclinical AF, new AF guidelines

  A recent article found that short-lasting, asymptomatic intervals of atrial fibrillation (“subclinical atrial fibrillation”)   were  associated with a significantly increased risk of stroke; and apixaban, vs aspirin, was effective in decreasing stroke or systemic embolism, though at a cost of increased bleeding  (see  afib subclinical apix helps NEJM2023  in dropbox, or  DOI: 10.1056/NEJMoa2310234 )   Details : -- 4012 patients from 247 clinical sites  in  16 European and North American countries who had subclinical atrial fibrillation (SCAF) lasting 6 minutes to 24 hours,  as  determined  from  their long-term continuous monitoring with pacemakers or defibrillators, were randomized to apixaban 5 mg twice a day (2.5 mg if indicated) versus aspirin 81 mg daily, in the ARTESIA trial -- eligible participants also a CHA 2 DS 2 -VASc score of at least 3, and subsequent  protocol  amendments raised the minimum a...